Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 9/20 | 1.00 |
| ▸ | CDK2 | P24941 | 7/20 | 1.00 |
| ▸ | CCNE2 | O96020 | 3/20 | 1.00 |
| ▸ | CCNE1 | P24864 | 3/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 1.00 |
| ▸ | CDK5 | Q00535 | 2/20 | 1.00 |
| ▸ | CCNA2 | P20248 | 2/20 | 1.00 |
| ▸ | CCNA1 | P78396 | 2/20 | 1.00 |
| ▸ | CCNB2 | O95067 | 2/20 | 1.00 |
| ▸ | CCNB1 | P14635 | 2/20 | 1.00 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14182620 | 0.93 | CDK1 (0.87) | CDK1CDK2CCNE2CCNE1TDP1 | |
| SCHEMBL13252976 | 0.89 | CDK1 (0.81) | CDK1CDK2CCNE2CCNE1TDP1 | |
| SCHEMBL7173102 | 0.88 | CDK1 (0.78) | CDK1CDK2CCNE2CCNE1TDP1 | |
| SCHEMBL1216905 | 0.85 | CDK1 (1.00) | CDK1CDK2CCNE2CCNE1TDP1 | |
| SCHEMBL7999800 | 0.85 | CDK1 (0.74) | CDK1CDK2CCNE2CCNE1TDP1 | |
| SCHEMBL13497848 | 0.84 | CDK1 (0.73) | CDK1CDK2CCNE2CCNE1TDP1 | |
| SCHEMBL5828515 | 0.83 | CDK2 (0.74) | CDK1CDK2CCNE2CCNE1TDP1 | |
| SCHEMBL17450135 | 0.81 | CDK2 (1.00) | CDK1CDK2CCNE2CCNE1TDP1 | |
| SCHEMBL13170162 | 0.81 | CDK2 (1.00) | CDK1CDK2CCNE2CCNE1TDP1 | |
| SCHEMBL12981789 | 0.81 | CDK1 (0.69) | CDK1CDK2CCNE2CCNE1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3425 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250332145-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF CANCER | Piramal Enterprises Limited (IN) | 2025-10-30 | — | — | US | claimed |
| US-12383529-B2 | Pharmaceutical combination for the treatment of cancer | Piramal Enterprises Limited (IN) | 2025-08-12 | — | — | US | claimed |
| CN-120044159-A | Polygonatum sibiricum medicinal material species identification method based on polygonatum sibiricum characteristic compound and application | 河北北方学院 | 2025-05-27 | — | — | CN | claimed |
| EP-4529926-A1 | METHOD FOR TREATING CANCER BY COMBINING ALKYLATING AGENT PRODRUG AND CELL CYCLE INHIBITOR | Ascentawits Pharmaceuticals, Ltd. (CN) | 2025-04-02 | — | — | EP | claimed |
| US-12187698-B2 | Crystalline forms of C21H22Cl2N4O2 | BIOMED VALLEY DISCOVERIES, INC. (US) | 2025-01-07 | — | — | US | claimed |
| US-20250006331-A1 | QUANTITATIVE SYSTEMS PHARMACOLOGY METHODS FOR IDENTIFYING THERAPEUTICS FOR DISEASE STATES | UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION (US) | 2025-01-02 | — | — | US | claimed |
| CN-119233822-A | Methods of treating cancer using alkylating agent prodrugs and cell cycle inhibitors in combination | 深圳艾欣达伟医药科技有限公司 | 2024-12-31 | — | — | CN | claimed |
| US-20240390325-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF CANCER | Piramal Enterprises Limited (IN) | 2024-11-28 | — | — | US | claimed |
| WO-2024189434-A1 | USE OF NADOLOL TO TREAT PULMONARY SYMPTOMS ASSOCIATED WITH INFECTIONS WITH SARS-CoV-2 | CHRONIC AIRWAY THERAPEUTICS LIMITED (AU) | 2024-09-19 | — | — | WO | claimed |
| US-20240287615-A1 | CANCER METHODS | UNIVERSITY COLLEGE LONDON (GB) | 2024-08-29 | — | — | US | claimed |
| EP-0784423-B1 | PLANTS WITH DELAYED OR INHIBITED RIPENING OR SENESCENCE | NOVARTIS AG (CH) | 2000-10-11 | — | — | EP | claimed |
| US-6087366-A | Use of flavopiridol or a pharmaceutically acceptable salt thereof for inhibiting cell damage or cell death | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2000-07-11 | — | — | US | claimed |
| EP-1003519-A1 | SUPRESSION OF CYCLIN KINASE 2 ACTIVITY FOR PREVENTION AND TREATMENT OF DNA VIRAL INFECTIONS | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2000-05-31 | — | — | EP | claimed |
| WO-2000029427-A2 | ANTENNAPEDIA HOMEODOMAIN HELIX 3 DERIVED TRANSLOCATION VECTORS | CYCLACEL LIMITED (GB) | 2000-05-25 | — | — | WO | claimed |
| EP-0985339-A1 | Plants with delayed or inhibited ripening or senescence | Novartis AG (CH) | 2000-03-15 | — | — | EP | claimed |
| WO-2000006170-A1 | INHIBITORS OF HERPESVIRUS GENE EXPRESSION, REPLICATION AND PATHOGENESIS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2000-02-10 | — | — | WO | claimed |
| WO-2000001417-A1 | DELIVERY SYSTEM | CYCLACEL LIMITED (GB) | 2000-01-13 | — | — | WO | claimed |
| WO-1999041984-A9 | INTERACTION BETWEEN THE MEC1-DEPENDENT DNA SYNTHESIS CHECKPOINT AND G1 CYCLIN FUNCTION IN $i(SACCAROMYCES CEREVISIAE) | HUTCHINSON FRED CANCER RES (US) | 1999-11-04 | — | — | WO | claimed |
| WO-1999041984-A1 | INTERACTION BETWEEN THE MEC1-DEPENDENT DNA SYNTHESIS CHECKPOINT AND G1 CYCLIN FUNCTION IN $i(SACCAROMYCES CEREVISIAE) | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 1999-08-26 | — | — | WO | claimed |
| WO-1998039007-A1 | SUPRESSION OF CYCLIN KINASE 2 ACTIVITY FOR PREVENTION AND TREATMENT OF DNA VIRAL INFECTIONS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1998-09-11 | — | — | WO | claimed |